Belantamab Mafodotin Combo Showed Promise in Myeloma Study
The BCMA-directed treatment offers a new off-the-shelf option for patients with relapsed or refractory multiple myeloma.
Updated on Oct. 7, 2026 in Cancer
New clinical data presented by Dr. Paul Richardson highlights the efficacy of a belantamab mafodotin combination regimen for patients with relapsed or refractory multiple myeloma. This therapy offers an outpatient treatment alternative for individuals who may not be candidates for CAR T-cell therapy or bispecific antibodies.
Why it matters
Expanding the availability of BCMA-directed therapies is critical for patients who cannot access specialized cellular treatments. This approach provides a practical, off-the-shelf option that simplifies access to care for individuals managing advanced myeloma.
The DREAMM-7 study evaluated outcomes for a belantamab mafodotin combination regimen in patients with relapsed or refractory multiple myeloma. While clinical outcomes have been reported, researchers are continuing to monitor long-term survival trends.
The players
Dr. Paul Richardson
A medical researcher focused on myeloma clinical trials and the development of new treatment regimens.
The details
Belantamab mafodotin functions as a BCMA-directed antibody-drug conjugate that targets B-cell maturation antigen to disrupt cancer cell growth. To safely integrate this into outpatient care, providers utilize specific dosing adjustments and mandatory ocular monitoring protocols to mitigate the risk of ocular toxicity associated with the drug.
Timeline
October 7, 2026: Clinical data from the DREAMM-7 study was presented.
Health Landscape
The findings from the DREAMM-7 study build on the ongoing evolution of BCMA-directed therapies for blood cancers. This approach represents a shift toward more accessible, off-the-shelf interventions as alternatives to labor-intensive cellular therapies.
If you are managing relapsed multiple myeloma, this therapy presents a new potential option to discuss with your oncology team regarding your eligibility. Your physician can help evaluate if this outpatient regimen is suitable based on your prior treatments and history of side effects.
The takeaway
BCMA-directed therapies continue to expand the treatment landscape for refractory myeloma patients. Patients and their families should speak with an oncologist about whether emerging off-the-shelf options fit their current clinical profile and care goals.
Further reading
For more information on current standard care and innovations, visit our Cancer section.
Source note: This article includes information reported by OncLive.
